Compare IRON & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | NMM |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2020 | 2007 |
| Metric | IRON | NMM |
|---|---|---|
| Price | $76.82 | $88.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $103.17 | $103.00 |
| AVG Volume (30 Days) | ★ 939.1K | 141.8K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | ★ 0.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.14 |
| Revenue Next Year | N/A | $4.62 |
| P/E Ratio | ★ N/A | $7.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.00 | $45.66 |
| 52 Week High | $99.50 | $97.00 |
| Indicator | IRON | NMM |
|---|---|---|
| Relative Strength Index (RSI) | 64.49 | 44.29 |
| Support Level | $73.04 | $87.25 |
| Resistance Level | $83.09 | $91.96 |
| Average True Range (ATR) | 3.70 | 2.33 |
| MACD | 2.43 | -0.84 |
| Stochastic Oscillator | 81.23 | 18.39 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.